[Antihistaminic therapy of chronic urticaria. Results of a multicenter study with azatadine and terfenadine].
A comparative double-blind multicenter trial was carried out in six German dermatology clinics involving patients with long-term continuous urticaria. After a five-day washout and initial assessment of the urticaria symptomatology oral antihistamine treatment was started with 2 X 1 mg Azatadine or 2 X 60 mg Terfenadine daily. After seven to ten days' treatment the target symptoms wheals, erythema and itching recovered in all but 4% of the azatadine patients and 21% of the terfenadine patients. Azatadine showed significantly stronger antiallergic efficacy for all symptoms. Both substances caused a certain degree of sedation, but in varying intensity. In all patients developing sedation this undesired side effect disappeared after three days in spite of continuous therapy.
D000328:Adult; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003533:Cyproheptadine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D008297:Male; D012894:Sleep Stages; D016593:Terfenadine; D014581:Urticaria / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D003533:Cyproheptadine; D016593:Terfenadine; C006656:azatadine
Antihistaminika-Behandlung bei chronischer Urtikaria. Ergebnisse einer Multicenter-Studie mit Azatadin und Terfenadin.